Cholinergic Supersensitivity in Affective Disorders

  • Sanjay Dubé
Part of the The Depressive Illness Series book series (DISS, volume 3)


Disturbance of cholinergic regulation is implicated in the aetiology of affective disorders, with some indication that the defect may lie at the level of the central muscarinic cholinergic receptors. Although direct experimental evidence in support of this hypothesis is lacking because of the absence of an “ideal” model to study m-cholinoceptor sensitivity in psychiatric patients, there is a large body of indirect data that points toward a cholinergic supersensitivity in mood disorders. Some of the controversies in support of this theory may be better understood with the identification and cloning of the muscarinic cholinergic receptor subtypes (M1–M5), each with a unique pharmacological profile and distribution in different regions of the brain.


Affective Disorder Muscarinic Receptor Muscarinic Cholinergic Receptor Cholinergic Mechanism Affective Illness 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Aalto J, Hilakivi Z: Difference in sleep wake patterns of the AA and ANA rat lines developed for high and low alcohol intake. Alcohol 1988; 3 (1): 77–79.Google Scholar
  2. Avery D, Wilschiotz G, Rafaelsen O: REM latency and temperature in affective disorders before and after treatment. Biot Psychiat 1982; 17: 463–470.Google Scholar
  3. Ben-Barak Y, Dudai Y: Scopolamine induces an increase in muscarinic receptor level in rat hippocampus. Brain Res 1980; 193: 309–313.PubMedGoogle Scholar
  4. Berger M, Doerr P, Lund R, Bronisch T, Zerssen von D: Neuroendocrinological and neurophysiological studies in major depressive disorders: Are there biological markers for the endogenous subtype? Biol Psychiat 17: 1217–1242.Google Scholar
  5. Birdsall NJM, Huhme EC: Biochemical studies on muscarinic acetylcholine receptors. J Neurochem 1976; 27: 7.PubMedGoogle Scholar
  6. Blake CA, Norman RL, Scaramuzzi RJ, Sawyer CH, Bolin RR: Psychiatric manifestations of artane toxicity. J Nery Ment Dis 1960; 131: 256–259.Google Scholar
  7. Bowers MB, Hartmann EL, Freedman DY: Sleep deprivation and brain acetylcholine. Science 1966; 153: 1416–1417.PubMedGoogle Scholar
  8. Bowers MB, Goodman E, Sim VM: Some behavioral changes in man following anticholinesterase administration. J Nery Ment Dis 1964; 138: 383.Google Scholar
  9. Bradbury MW, Burden BJ, Hillhouse EW, Jones MT: Stimulation electrically and by acetylcholine of the rat hypothalamus in vitro. J Physiol (Lond) 1974; 239: 269–283.Google Scholar
  10. Bruni JF, Meites J: Effects of cholinergic drugs on growth hormone release. Life Sci. 1978; 23: 1315–1358.Google Scholar
  11. Byrne MC, Gottlieb N, McNamara TO: Amygdala kindling induces muscarinic cholinergic receptor declines in a highly specific distribution within the limbic system. Symp Neurol 1980; 69: 85–98.Google Scholar
  12. Carroll BJ, Feinberg M, Greden JF et al: A specific laboratory test for the diagnosis of melancholia. Arch Gen Psychiat 1981; 38: 15–22.PubMedGoogle Scholar
  13. Carroll BJ, Greden JF, Hasket R et al: Neurotransmitter studies of neuroendocrine pathology in depression. Acta Psychiat Scand 1980; 61; Suppl 280: 183–199.Google Scholar
  14. Carroll BJ, Frazer A, Schiess A, Mendels J: Cholinergie reversal of manic symptoms. Lancet 1973; i: 427.Google Scholar
  15. Chouvet G, Blois R, Debilly G, Jouvet M: The structure of the occurrence of rapid eye movements in paradox sleep is similar in homozygotic twins. C R Seances Acad Sci (III) 1983; 296 (22): 1063–1068.Google Scholar
  16. Chouvet G: Structures d’occurrence des activite’s phasiques du sommeil paradoxal chez l’animal et chez l’homme. Ph.D. diss., Université Claude-Bernard, Lyons, France, 1991.Google Scholar
  17. Cioro W, Marchesi D, DeFerri A, Mosti A, Delsingnore R, Govi AM, Gnudi A, Chiodera P: Pirenzepine inhibits growth hormone, but not thyrotropin response to thyrotropin-releasing hormone in patients with endogenous depression. Psychoneuroendocrinology 1987; 12: 313–317.Google Scholar
  18. Coble P, Kupfer DJ, Shaw DH: Distribution of REM latency in depression. Biol Psychiat 1981; 16: 453–466.PubMedGoogle Scholar
  19. Cohen BM, Lipinsky JF, Altesmar RF: Lecithin in the treatment of mania. Am J Psychiat 1982; 139: 1162–1164.PubMedGoogle Scholar
  20. Cozanitis DA: Galanthamine hydrobromide versus neostigmine. Anaesthesia 1974; 29: 163–168.PubMedGoogle Scholar
  21. Crashaw JA, Mullen PE: A study of Benzhexol abuse. Br J Psychiat 145: 300–303.Google Scholar
  22. Dasheiff RM, Savage DD, McNamara JO: Seizures down-regulate muscarinic cholinergic receptors in hippocampal formation. Brain Res 1982; 235: 327–334.PubMedGoogle Scholar
  23. Daszuta A, Gambarelli G: Early postnatal development of EEG and sleep wak- ing cycle in two inbred mouse strains. Brain Res. 1985; 354 (1): 39–47.PubMedGoogle Scholar
  24. Davis BM, Davis KL: Cholinergic mechanisms and anterior pituitary secretion. Biol Psychiat 1981; 303–310.Google Scholar
  25. Delitala G, Maioli M, Pacifico A, Brianda SA, Palermo M, Manneli M: Cholinergic receptor control mechanisms for L-dopa, apomorphine and clonidineinduced growth hormone secretion in man. J Clin Endocrinol Metab 1983; 57: 1145–1149.PubMedGoogle Scholar
  26. Dilsaver SC, Davidson RK: Chronic treatment with amitriptyline produces sub-sensitivity to the hypothermic effects of yohimbine. Progr Neuropsychopharmacol Biol Psychiat 1989; 13: 211–215.Google Scholar
  27. Dilsaver SC, Hariharan M: Nicotinic effects of antidepressants. In: Gershon S, Lerer B (Eds.), New Directions in Affective Disorders, Springer, New York, 1989, 109–112.Google Scholar
  28. Dilsaver SC, Majchrzak MJ: Bright artificial light produces subsensitivity to nicotine. Life Sci 1989; 42: 225–230.Google Scholar
  29. Dilsaver SC: The pathophysiologies of substance abuse and affective disorders: An integrative model? J Clin Psychopharmacol 1987; 7: 1–10.PubMedGoogle Scholar
  30. Dilsaver SC, Davidson RK: Effect of chronic cold room stress on the hypothermic response to oxotremorine. Biol Psychiat 1987a; 22: 1051–1052.PubMedGoogle Scholar
  31. Dilsaver SC, Davidson RK: Fluoxetine subsensitizes a nicotinic mechanism involved in the regulation of core temperature. Life Sci 1987b; 41: 1165–1169. Dilsaver SC, Snider RM, Alessi NE: Amitriptyline supersensitizes a central cholinergic mechanism. Biol Psychiat 22: 495–507.Google Scholar
  32. Dilsaver SC: Cholinergic mechanisms in affective disorders: Future directions for investigation. Acta Psychiat Scand 1986a; 74: 312–334.PubMedGoogle Scholar
  33. Dilsaver SC: Pathophysiology of cholinergic supersensitivity in affective disorders. Biol Psychiat 1986b; 21: 813–829.PubMedGoogle Scholar
  34. Dilsaver SC: Cholinergic mechanisms in depression. Brain Res Rev 1986c; 11: 285–316.Google Scholar
  35. Dilsaver SC, Greden JF: Antidepressant withdrawal-induced activation (hypo-mania and mania): Mechanisms and theoretical significance. Brain Res Rev. 1984; 7: 29–48.Google Scholar
  36. Doerr P, Berger M: Physostigmine-induced escape from dexamethasone in normal subjects. Biol Psychiat 18: 261–268.Google Scholar
  37. Dubé S, Sitaram N: Familial inheritance of REM sleep % and arecoline induction response in association with major affective illness. Abstracts of the Proceedings of the CINP, Munich, 1988.Google Scholar
  38. Edelstein CK, Roy-Byrne P, Fawzy FI et al: Effects of weight loss on the dexamethasone suppression test. Am J Psychiat 1983; 140: 338–341.PubMedGoogle Scholar
  39. Edwardson JA, Bennett GW: Modulation of corticotropin-releasing factor release from hypothalamic synaptosomes. Nature 1974; 251: 425–427.PubMedGoogle Scholar
  40. Ehlert FJ, Roeske WR, Yamamura HI: Muscarinic cholinergic receptor heterogeneity. Trends Neurosci 1982; 5: 336.Google Scholar
  41. El-Fakahany E, Richelson E: Effect of some calcium antagonists on muscarinicmediated cyclic GMP formation. J Neurochem 40: 705–710.Google Scholar
  42. El-Yousef MK, Janowsky DS, Davis JM et al: Induction of severe depression by physostigmine in marijuana intoxicated individuals. Br J Addiction 68: 321–325.Google Scholar
  43. Ferrari E, Bossolo PA, Vailati A, Martinelli I, Rea A, Nosari I: Variations ciracadiennes des effects d’une substance vagolytique sur le system ACTHsecretant chez l’homme. Ann Endocrinol (Paris) 1977; 308: 203–213.Google Scholar
  44. Frey KA, Ehrenkaufer S, Beaucage S, Agranoff BW: Quantitative in vivo receptor binding I. Theory and application of the muscarinic cholinergic receptor. J Neurosci 1985; 5: 421–428.PubMedGoogle Scholar
  45. Frey KA, Ehrenkaufer RLL, Agranoff R: Quantitative in vivo receptor binding II. Autoradiographic imaging of muscarinic cholinergic receptors. Neuroscience 1985; 5: 2407–2414.PubMedGoogle Scholar
  46. Friedmann JK: A diallel analysis of the genetic underpinnings of mouse sleep. Physiol Behav 12: 169–175.Google Scholar
  47. Friedman MJ, Jaffe J: A central hypothermic response to pilocarpine in the mouse. J Pharmacol Exp Ther 1969; 167: 34–44.PubMedGoogle Scholar
  48. Ganong WF: Neurotransmitters in pituitary function: Regulation of ACTH secretion. Fed Proc 1980; 39: 2923–2930.PubMedGoogle Scholar
  49. Gershon S, Shaw FH: Psychiatric sequelae of chronic exposure to organophosphorus insecticides. Lancet 1961; i: 1371–1374.Google Scholar
  50. Gibbs DN, Plotsky PM, deGreef WJ, Neill JD: Effect of histamine and acetylcholine on hypophyseal stalk plasma dopamine and peripheral prolactin levels. Life Sci 1979; 24: 2063–2070.PubMedGoogle Scholar
  51. Gillin JC, Janowsky DS, Risch SC: The cholinergic REM induction test (CRIT): A replication. In: Chase MH, McGinty DJ, O’Connor C (Eds.), Sleep Research, Los Angeles: University of California, 1988a, Vol. 17, 123.Google Scholar
  52. Gillin JC, Risch SC, Janowsky DS: The cholinergic REM delay test: A preliminary comparison of depressives and controls. In: Chase MH, McGinty DJ, O’Connor C (Eds.), Sleep Research 1988b, Vol. 17, 124.Google Scholar
  53. Gillin JC, Sitaram N, Wehr T et al: Sleep and affective illness. In: Post RM, Ballenger JC (Eds.), Neurobiology of Mood Disorders, Baltimore: Williams and Wilkins, 1984, 157–189.Google Scholar
  54. Gillin JC: Sleep studies in affective illness: Diagnostic, therapeutic, and pathophysiological implications. Psychiat Ann 1982; 13: 367–384.Google Scholar
  55. Gillin JC, Duncan WC, Pettigrew KD, Frankel BL, Snyder F: Successful separation of depressed, normal, and insomniac subjects by EEG sleep data. Arch Gen Psychiat 1979b; 36: 85–90.PubMedGoogle Scholar
  56. Gillin JC, Sitaran N, Duncan WC: Muscarinic supersensitivity: A possible model for the sleep disturbance of primary depression? Psychiat Res 7: 17–22.Google Scholar
  57. Glen AIM, Ongley EC, Robinson K: Diminished membrane transport in manicdepressive psychosis and recurrent depression. Lancet 1968; 2: 241–242.PubMedGoogle Scholar
  58. Golden RN, Potter WZ: Neurochemical and neuroendocrine dysregulation in affective disorders. Psychiat Clin N Am 1986; 9: 313–327.Google Scholar
  59. Goldman ME, Erickson CK: Effects of acute and chronic administration of antidepressant drugs in the central cholinergic nervous system: comparison with anticholinergic drugs. Neuropharmacology 1983; 22: 1222–1285.Google Scholar
  60. Grandison L, Meites J: Evidence for adrenergic medication of cholinergic inhibition of prolactin release. Endocrinology 1976a; 99: 775–779.PubMedGoogle Scholar
  61. Hedge CA, De Wied D: Corticotropin and vasopressin secretion after hypothalamic implantation of atropine. Endocrinology 1971; 88: 1257–1259.PubMedGoogle Scholar
  62. Hillhouse EW, Burden J, Jones MT: The effects of various putative neurotransmitters on the release of corticotropin releasing hormone from the hypothalamus of the rat in vitro. I. The effect of acetylcholine and nor-adrenaline. Neuroendocrinology 1975; 17: 1–11.PubMedGoogle Scholar
  63. Hill P, Wyndber EL: Smoking and cardiovascular disease. Am Heart J 1974; 87: 491–496.PubMedGoogle Scholar
  64. Hobson JA: The reciprocal interaction model of sleep cycle control: Discussion in the light of Giuseppe Moruzzi s concepts. In: Pompeiano O, Ajmone N (Eds.) Brain Mechanisms and Perceptual Awareness, New York: Raven, 1981, 379–404.Google Scholar
  65. Hobson JA, McCarley RW, Wyzinksi PW: Sleep cycle oscillation: Reciprocal discharge by two brainstem neuronal groups. Science 1975; 189: 55–58. Google Scholar
  66. Hobsen JA, McCarley RW, Pivik RT, Freedman R: (1974). Selective firing by cat pontine brain stem neurons in desynchronized sleep. J Neurophysiol 1974; 38: 497–511.Google Scholar
  67. Hobson JA, McCarley RW: Spontaneous discharge rates of rat cerebellar purkinje cells in sleep and waking. Electroenceph Clin Neurophysiol 1972; 457–469.Google Scholar
  68. Insel TR, Kalin NH, Cohen RM, et al: Dexamethasone suppression test in pa- tients with obsessive compulsive disorder. Psychiat Res 1982; 6: 153–160.Google Scholar
  69. Jackson MD: Hypothalamic releasing hormones: Mechanisms underlying neuroendocrine dysfunction in affective disorders. In: Brown GM, Koslow SH, Reichlin S (Eds.), Neu roendocrinology and Psychiatric Disorder, Raven Press, New York, 255–256.Google Scholar
  70. Jaffe JH, Sharpless SK: Pharmacological denervation supersensitivity in the central nervous system. Res Pub Assoc Res Nery Ment Dis (1968); 46: 226–241.Google Scholar
  71. James SP, Wehr TA, Sack DA, Parry BL, Rosenthal NE: Treatment of seasonal affective disorder with light in the evening. Br J Psychiat 1985; 147: 424–485.Google Scholar
  72. Janowsky DS, Risch SC, Huey LY, Kennedy B, Zigler M: Effects of physostigmine on pulse, blood pressure, and serum epinephrine levels. Am J Psychiat 1985; 142: 738–740.PubMedGoogle Scholar
  73. Janowsky DS, Risch SC: Cholinomimetic and anticholinergic drugs used to investigate an acetylcholine hypothesis of affective disorders in stress. Drug Dey Res 1984; 4: 125–142.Google Scholar
  74. Janowsky DS, Risch SC, Huey L, Judd L, Rousch J: Central physostigmine-induced cardiovascular and behavioral changes: Toward an acetylcholine hypothesis of stress. Psychopharmacol Bull 19: 675–682.Google Scholar
  75. Janowsky DS, Risch SC, Gillin JC: Adrenergic-cholinergic balance and the treatment of affective disorders. Prog. Neuro-Psychopharmacol Biol Psychiat 1983b; 7: 297–307.Google Scholar
  76. Janowsky DS, Judd LL, Groom G: The influence of lithium on cholinergic function. Proceedings of the 12th Collegium Internationale NeuroPsychopharmacologicum Congress, Jerusalem, Israel, 1982a.Google Scholar
  77. Janowsky DS, Risch SC, Huey LY, Judd LL, Rausch JL: Physostigmine-induced cardiovascular changes, behavioral and neuroendocrine correlations. Presented at the Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, 1982b.Google Scholar
  78. Janowsky DS, Abrams AA, Groom GP, Judd LL, Clopton P: Lithium administration antagonizes cholinergic behavioral effects in rodents. Psycho pharmacology 1979; 63: 147–150.Google Scholar
  79. Janowsky DS, Davis JM, El-Yousef MK, Sekerke HJ: Acetylcholine and depression. Psychosom Med 1973a; 35 (5): 459.Google Scholar
  80. Janowsky DS, El-Yousef MK, Davis JM, Sererke HS: Parasympathetic suppression of manic symptoms of physostigmine. Arch Gen Psychiat 1973b; 38: 542–547.Google Scholar
  81. Janowsky DS, El-Yousef MK, Davis JM, Sekerke HJ: Antagonistic effects of physostigmine and methylphenidate in man. Am J Psychiat 1973c; 130: 13701376.Google Scholar
  82. Janowsky DS, El-Yousef MK, Davis JM, Sererke HS: A cholinergic adrenergic hypothesis of mania and depression. Lancet 1972; 2: 632–635.PubMedGoogle Scholar
  83. Jellinec T, Gardos G, Cole J: Adverse effects of antiparkinsonian drug withdrawal. Am J Psychiat 1981; 138: 1567–1571.Google Scholar
  84. Jimmerson DC, Nurnberger JI, Simmons S, Gershon ES: Anticholinergic treatment for depression. (Presented at the 135th Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 15–21). Syllabus 1982; 218–219.Google Scholar
  85. Jones D, Kelwala S, Bell J, et al: Cholinergic REM sleep induction response—Correlation with endogenous major depressive subtype. Psychiat Res 1985; 14: 99–110.Google Scholar
  86. Jope RS: Effects of lithium treatment in vivo and in vitro on acetylcholine metabolism in rat brain. J Neurochem 1979; 33: 487–495.PubMedGoogle Scholar
  87. Jouvet M: Cholinergic mechanisms and sleep. In: Waser PG (Ed.) Cholinergie Mechanisms, New York: Raven, 1975, 455–476.Google Scholar
  88. Judd LL, Hubbard B, Janowsky DS, Huey LY, Attewell PA: The effect of lithium carbonate on affect, mood and personality of normal subjects. Arch Gen Psychiat 1977; 34: 346–351.PubMedGoogle Scholar
  89. Kaminer Y, Munitz H, Wijsenbelc H: Trihyzyphenidyl (artane) abuse: Euphoriant and anxiolytic. Br J Psychiat 1982; 140: 473–474.Google Scholar
  90. Karczmar AG, Longo VG, Sotti De Carolis A: A pharmacological model of paradoxical sleep: The role of cholinergic and monoamine systems. Physiol Behav 1976; 5: 175–182.Google Scholar
  91. Kasper S, Moises HW, Beckman H: The anticholinergic biperidin in depressive disorders. Pharmacopsychiatry 1981; 14: 195–198.Google Scholar
  92. Kaufmann CA, Gillin JC, Hill B, O’Laughlin T, Phillips I, Kleinman JE, Wyatt RI: Muscarinic binding in suicides. Psychiat Res 1984; 12: 47–55.Google Scholar
  93. Kelsoe JR, Gillin JE, Janowsky DJ, Brown JH, Risch SC, Lunkin B: Failure to conform muscarinic receptors on skin fibroblasts. N Engl J Med 1984; 312: 861–862.Google Scholar
  94. Kelwala S: Enhanced pilocarpine miosis in depressed patients. Presented at the 137th Annual Meeting of the American Psychiatric Association in Los Angeles, California, May 5–11, NR25, 1984.Google Scholar
  95. Kennedy S, Thompson R, Stancer HC, Roy A, Persad E: Life events precipitating mania. Br J Psychiat 1983; 142: 398–403.Google Scholar
  96. Keneko FM: Neurotransmitters involved in ACTH secretion: Catecholamines. Ann NY Acad Sci 1977; 297: 509–517.Google Scholar
  97. Krieg JC, Berger M: REM sleep and cortisol response to the cholinergic challenge with RS 86 in normals and depressives. Acta Psychiat Scand 1987; 76: 600–602.PubMedGoogle Scholar
  98. Krieg JC, Berger M: Impact of the cholinergic system on the hypothalamicpituitary-adrenocortical axis and on REM sleep. In: Lerer B, Gershon S (Eds.), New Directions in Affective Disorders, New York: Springer-Verlag, 71–74.Google Scholar
  99. Kumbarachi MN, Nastuk WL: Effects of delta 9-tetrahydrocannabinol on excitable membranes and neuromuscular transmission. Mol Pharmacol 1980; 17: 344–345.Google Scholar
  100. Kupfer DJ, Hanin I, Spiker DG, Neil J, Coble P: EEG sleep and tricyclic plasma levels in primary depression. Commun Psychopharmacol 1979; 3: 73–80.PubMedGoogle Scholar
  101. Kupfer DJ: REM latency: A psychobiological marker for primary depressive disease. Biol Psychiat 1976; 11: 159–174.PubMedGoogle Scholar
  102. Kupfer DJ, Foster FG: Interval between onset of sleep and rapid eye movement as an indicator of depression. Lancet 1972; 2: 684–686.PubMedGoogle Scholar
  103. Leckman et al: Panic disorder and major depression. Arch Gen Psychiat 1983; 40: 1055–1060.PubMedGoogle Scholar
  104. Lennox RH, Hitzemann RJ, Richelson E, Kelsoe JR: Failure to confirm muscarinic receptors on skin fibroblasts in familial affective disorder. N Engl J Med 1984; 311: 225–230.Google Scholar
  105. Lewy AJ, Sack RL: Phase typing and bright light therapy of chronobiologic sleep and mood disorders. In: Halaris A (Ed.), Chronobiology and Psychiatric Disorders, New York: Elsevier, 1987, 181–206.Google Scholar
  106. Lewy AJ, Sack RL, Fredrickson RH, et al: The use of bright light in treatment of chronobiologic sleep and mood disorders: The phase-response curve. Psychopharmacol Bull 1983; 9: 523–525.Google Scholar
  107. Lewy AJ, Kern HA, Rosenthal NE, Wehr TA: Bright artificial light treatment of a manic-depressive patient with seasonal mood cycle. Am J Psychiat 1982; 139: 1496–1498.PubMedGoogle Scholar
  108. Lindemann E, Finesinger JE: The subjective response of psychoneurotic patients to adrenaline and mecolyl. Psychosom Med 1940; 2: 231–246.Google Scholar
  109. Lloyd C: Life events and depressive disorder: II. Events as precipitating factors. Arch Gen Psychiat 1980; 37: 541–548.PubMedGoogle Scholar
  110. Lomax P, Jenden DJ: Hypothermia following systemic and intracerebral injection of oxotremorine in the rat. Neuropharmacology 1966; 5: 353–359.Google Scholar
  111. Makara GB, Stark E: The effects of cholinomimetic drugs and atropine on ACTH release. Neuroendocrinology 1976; 21: 31–41.PubMedGoogle Scholar
  112. McCarley RW: REM sleep and depression—common neurobiological control mechanisms. Am J Psychiat 1982; 139: 565–570.PubMedGoogle Scholar
  113. Mendelson WB, Jacobs LS, Sitaram N, Wyatt RJ, Gillin JC: Methscopolamine inhibition of sleep-related growth hormone secretion. Evidence for a cholinergic secretory mechanism. J Clin Invest 1978; 61: 1683–1686.PubMedGoogle Scholar
  114. Meyerson LR, Wennogle LP, Abel MS, Coupet J, Lippa AS, Rauh CE, Beer B: Human brain receptor alterations in suicide victims. Pharmacol Biochem Behav 1982; 17: 159–163.PubMedGoogle Scholar
  115. Modestin JJ, Hunger J, Schwartz RB: Uber die depressogene wirkung von physostigmine. Arch Psychiatr Nervenkr 1973a; 218: 67.PubMedGoogle Scholar
  116. Modestin JJ, Schwartz RB, Hunger J: Zur frage der beeinflussung schizophrener symptome physostigmine. Pharmakopsychiatrie 1973b; 9: 300–304.Google Scholar
  117. Nassrallah HA, Coryell WA: Dexamethasone non-suppression predicts the antidepressant effects of sleep deprivation. Psychiat Res 1982; 6: 61–64.Google Scholar
  118. Naumenko EB: Hypothalamic chemoreactive structures and the regulation of pituitary-adrenal function. Effects of local injections of norepinephrine, carbacol and serotonin into the brain of guinea pigs with intact brains and after mesencephalic transaction. Brain Res 1968; 11: 1–10.PubMedGoogle Scholar
  119. Naylor GJ, Dick DAT, Dick EG, et al: Erythrocyte membrane cation carrier in mania. Psychol Med 1976; 6: 659–663.PubMedGoogle Scholar
  120. Neil JF, Himmelhoch JM, Licata SM: Emergence of myasthenia gravis during treatment with lithium carbonate. Arch Gen Psychiat 1976; 33: 1090–1092.PubMedGoogle Scholar
  121. Nomura Y, Kajiyama H, Segawa T: Possible influence of noradrenalin on Badrenergic and muscarinic receptors in rat heart: Effects of 6-hydroxydopamine, isoproterenol and dimethylimipramine. In Segawa T (Ed.), Molecular of Neurotransmitter Receptors, New York: Raven Press, 1983, 83–90.Google Scholar
  122. Nomura Y, Kajiyama H, Segawa T: Alteration in sensitivity to isoproterenol and acetylcholine in rat heart after repeated administration of isoproterenol. J Pharmacol Exp Ther 1982; 220: 441–445.Google Scholar
  123. Nurnberg JI, Jr, Sitaram N, Gershon ES, Gillin JC: Biol Psychiat 1983; 18: 1161–1165.Google Scholar
  124. Nurnberg J, Gershon ES, Sitaram N, Gillin JC, Brown G, Ebert M, Gold P, Jimmerson D, Kessler L: Dextroamphetamine and arecoline as pharmacogenetic probes in normals and remitted bipolar patients. Psychopharmacol Bull 1982a; 17: 80–82.Google Scholar
  125. Nurnberg JI, Jimerson DC, Simmons S, Tammings C, Nadi NS, Gershon ES: Responses to arecoline in normal twins and “well state” patients with affective disorder. Presented at the Society of Biological Society, 13th Annual Convention, Toronto, 1982b.Google Scholar
  126. Oppenheimer G, Ebstein R, Belmaker R: Effects of lithium on the physostigmineinduced behavioral syndrome and plasma cyclic GMP. J Psychiat Res. 1979; 14: 133–138.Google Scholar
  127. Overstreet DH: Genetic animal model of depression with cholinergic supersensitivity. New Directions Affect Disord 1989; 14: 67–69.Google Scholar
  128. Overstreet DH: Selective breeding for increased cholinergic function: Development of a new animal model of depression. Biol Psychiat 1986a; 21: 49–58.PubMedGoogle Scholar
  129. Overstreet DH, Janowsky DS, Gillin JC, Shiromani P, Sutin E: Stress-induced immobility in rats with cholinergic supersensitivity. Biol Psychiat 1986b; 21: 657–664.PubMedGoogle Scholar
  130. Overstreet DH, Booth RA, Dana R, Risch SC, Janowsky DS: Enhanced elevation of corticosterone following arecoline administration to rats selectively bred for increased cholinergic function. Psychopharmacology 1986c; 88: 129–130.PubMedGoogle Scholar
  131. Overstreet DH: Selective breeding for increased cholinergic sensitivity: Implications for animal models of depression. Soc Neurosci Abstr 1984; 10: 289.Google Scholar
  132. Overstreet DH, Russell RW: Selective breeding for differences in cholinergic function: Sex differences in the genetic regulation of sensitivity to the anti-cholinesterase, DFP. Behav Neurol Biol 1984; 40: 227–238.Google Scholar
  133. Overstreet DH, Russell RW: Selective breeding for sensitivity to DFP: Effects of cholinergic agonists and antagonists. Psychopharmacology 1982; 78: 150–154.PubMedGoogle Scholar
  134. Overstreet DH, Russell RW, Helps SC, Messenger M: Selective breeding for sensitivity to the anticholinesterase DFP. Psychopharmacology 1979; 65: 15–20.PubMedGoogle Scholar
  135. Overstreet DH, Kozar MP, Lynch GS: Reduced hypothermic effects of cholinomimetic agents following chronic anticholinesterase treatment. Neuropharmacology 1973; 12: 1017–1032.PubMedGoogle Scholar
  136. Palkovitz M: Neural pathways involved in ACTH regulation. Ann NY Acad Sci 1977; 297: 455–476.Google Scholar
  137. Pert A, Rosenblatt J, Sivit C, Pert CB, Bunney WB: Long term treatment with lithium prevents the development of dopamine receptor supersensitivity. Science 1978; 201: 171–173.PubMedGoogle Scholar
  138. Perry EK, Perry RH, Blessed G, Tomlinson BE: Necropsy evidence of central cholinergic deficits in senile dementia. Lancet I 1977; I: 189.Google Scholar
  139. Pullen GP, Best NR, Maguire J: Anticholinergic drug abuse. A common problem? Br Med J 1984; 2xx: 612–613.Google Scholar
  140. Rasmussen KLR, Reite M: Loss-induced depression in an adult Macaque monkey. Am J Psychiat 1982; 139: 681–697.Google Scholar
  141. Richardson SB, Hollander CS, D’Elletto R, Greenleaf PW, Thaw C: Acetylcholine inhibits the release of somatostatin from rat hypothalamus in vitro. Endocrinology 1980; 107: 122–129.PubMedGoogle Scholar
  142. Risch SC, Janowsky DS, Parker D, et al: Neuroendocrine abnormalities in affective disorders: Possible cholinergic mechanisms. In Post RM, Ballanger J (Eds.), The Neurobiology of Mood Disorders, Baltimore: Williams and Wilkins, 1984.Google Scholar
  143. Risch SC, Janowsky DS, Gillin JC: Muscarinic supersensitivity of.anterior pituitary ACTH and B-endorphin release in major depressive illness. Peptides 1983; 4: 789–792.PubMedGoogle Scholar
  144. Risch SC, Kalin NH, Janowsky DS, Cohen RM, Pickar D, Murphy DL: Response to central cholinergic stimulation. Science 1983; 77: 222.Google Scholar
  145. Risch SC: B-endorphin hypersecretion in depression: Possible cholinergic mechanisms. Biol Psychiat 1982; 17: 1071–1079.PubMedGoogle Scholar
  146. Risch SC, Janowsky DS, Judd LL, Rausch JL, Huey LY, Beckman KA, Cohen RM, Murphy DL: Cholinergically stimulated hypothalamic B-endorphin modulation of anterior pituitary prolactin release in humans. Peptides 1982; 3: 319–322.PubMedGoogle Scholar
  147. Risch SC, Cohen PM, Janowsky DS, Kalin N, Sitaram N, Gillin JC, Murphy DL: Physostigmine induction of depressive symptomatology in normal human subjects. J Psychiat Res 1981a; 4: 89–94.Google Scholar
  148. Risch SC, Kalin NH, Janowsky DS: Cholinergie challenges in affective illness: Behavioral and neuroendocrine correlates. J Clin Psychopharmacol 1981b; 1: 186–192.PubMedGoogle Scholar
  149. Risch SC, Cohen RM, Janowsky DS, Kalin NH, Murphy DL: Plasma B-endorphin and cortisol elevations accompany the mood and behavioral effects of physostigmine stimulation. Science 1980; 209: 1545–1546.PubMedGoogle Scholar
  150. Rosenberg RS, Bergmann BM, Jeonson H, Arnason BG, Rechtschaffen A: Strain differences in sleep of rats. Sleep 1987; 10 (6): 537–541.PubMedGoogle Scholar
  151. Rosenblatt JE, Janowsky DS, Davis JM, et al: The augmentation of physostigmine toxicity in the rat by delta 9-tetrahydrocannabinol. Res Commun Chem Pathol Pharmacol 1972; 3: 479–481.PubMedGoogle Scholar
  152. Rosenthal NE, Carpenter CJ, James SP, Parry BL, Rogers SLB, Wehr TA: Seasonal affective disorder in children and adolescents. Amer J Psychiat 1986; 3: 356–358.Google Scholar
  153. Rosenthal NE, Sack DA, Gillin JC, Levy JA, Goodwin FK, Davenport Y, Mueller PS: Seasonal affective disorder: A description of the syndrome and preliminary findings with light therapy. Arch Gen Psychiat 1984; 41: 72–80.PubMedGoogle Scholar
  154. Rowntree DW, Neven S, Wilson A: The effects of di-isopropylfluorophosphonate in schizophrenia and manic depressive psychosis. J Neurol Neurosurg Psychiat 1950; 13: 47–62.PubMedGoogle Scholar
  155. Rubinstein JS: Abuse of antiparkinsonism drugs: Feigning of extraphyramidyl symptoms to obtain trihexphenidyl. J Am Med Assoc 1978; 239: 2365–2366.Google Scholar
  156. Sagelas T, Erill S, Domino EF: Differential effects of scopolamine and chlorpromazine on REM and NREM sleep in normal male subjects. Clin Pharmacol Ther 1969; 10: 522–529.Google Scholar
  157. Samples J, Janowsky DS, Pechnick R, Judd LL: Lethal effects of physostigmine plus lithium in rats. Psychopharmacology 1977; 52: 307–309.PubMedGoogle Scholar
  158. Shiromani PJ, Overstreet D, Levy D, Goodrich CA, Campbell SS, Gillin JC: Increased REM sleep in rats selectively bred for cholinergic hyperactivity. Neuropsychopharmacology 1988; 1: 127–133.PubMedGoogle Scholar
  159. Shopsin B, Janowsky DS, Davis JM, Gershon S: Rebound phenomena in manic patients following physostigmine. Neuropsychobiology 1975; 1: 180–187.PubMedGoogle Scholar
  160. Shur E, Checkley S, Delgado I: Failure of mianserin to affect autonomic function in the pupils of depressed patients. Acta Psychiat Scand 1983; 67: 50–55.PubMedGoogle Scholar
  161. Sitaram N, Nurnberger J, Gershon E, Gillin JC: Faster cholinergic REM sleep induction in euthymic patients with primary affective illness, Science 1980; 208: 200–202.PubMedGoogle Scholar
  162. Sitaram N, Nurnberg J, Gershon ES, Gillin JC: Cholinergic regulation of mood and REM sleep: A potential model and marker for vulnerability to affective disorder. Am J Psychiat 1982; 139: 571–576.PubMedGoogle Scholar
  163. Sitaram N, Gillin JC: Development and use of pharmacological probes of the CNS in man: Evidence of cholinergic abnormality in primary affective illness. Biol Psychiat 1980; 15: 925–955.PubMedGoogle Scholar
  164. Sitaram N, Nurnberger J, Gershon E, Gillin JD: Faster cholinergic REM inductions in euthymic patients with primary affective illness. Science 1980; 208: 200–202.PubMedGoogle Scholar
  165. Sitaram N, Mendelson WB, Wyatt RJ, Gillin JC: The time dependent induction of REM sleep and arousal by physostigmine infusion during normal human sleep. Brain Res 1977; 122: 562–567.PubMedGoogle Scholar
  166. Sitaram N, Dubé S, Keshavan M, Davies A, Reynal P. The association of supersensitive cholinergic REM-induction and affective illness within pedigrees. J Psychiat Res 1987; 21: 487–497.PubMedGoogle Scholar
  167. Sitaram N, Moore AM, Gillin JC: Scopolamine-induced muscarinic supersensitivity in normal man: Changes in sleep. Psychiat Res 1979; 1: 9–16.Google Scholar
  168. Spar JE, Cerner R: Does the dexamethasone suppression test distinguish dementia from depression? Am J Psychiat 1982; 139: 238–240.PubMedGoogle Scholar
  169. Spiker DG, Coble P, Cofsky J, Foster FG, Kupfer DJ: EEG sleep and severity of depression. Biol Psychiat 1978; 13: 485–488.PubMedGoogle Scholar
  170. Stanley M, Mann JJ: Increased serotonin-2 binding sites in frontal cortex of suicide victims. Lancet 1983; I: 214.Google Scholar
  171. Subramanian MG, Gala RR: The influence of cholinergic, adrenergic and serotonergic drugs on the afternoon surge of plasma prolactin in overiestomized, estrogen-treated rats. Endocrinology 1976; 98: 842–848.PubMedGoogle Scholar
  172. Taylor P: Cholinergic agonists. In: Gilman AG, Goodman LS, Gilman A (Eds.), The Pharmacological Basis of Therapeutics, 6th ed, New York: Macmillan, 1980.Google Scholar
  173. Terry LC, Crowley WR: Regulation of growth hormone and thyrotropin secretion by somatostatin systems in rat brain. Neuroendocrinology 1986; 42: 218–225.PubMedGoogle Scholar
  174. Tollefson GD, Senogles SE, Frey WH, et al: A comparison of peripheral and central human muscarinic cholinergic receptor affinities for psychotropic drugs. Biol Psychiat 1982; 17: 555–567.PubMedGoogle Scholar
  175. Trusihiya K, Toru M, Kobayashi T: Sleep deprivation: Changes of monoamine and acetylcholine. Life Sci 1969; 8: 867–873.Google Scholar
  176. Uhde T, Post RM, Bierer L: Caffeine-induced escape from dexamethasone suppression. Arch Gen Psychiat 42: 737–738. Google Scholar
  177. Valatx JL, Caspuglio R, Paut L, Bailey DW: Genetic study of paradox sleep in mice. Waking Sleep 1980; 4(2): 175–183. Google Scholar
  178. Webb WB, Campbell SS: Sleep characteristic relationship of identical and fraternal twins. Arch Gen Psychiat 1983; 40: 1093. Google Scholar
  179. Wehr TA, Goodwin FK: Rapid cycling manic-depressives induced by tricyclic antidepressants. Arch Gen Psychiat 1979; 15: 149–154. Google Scholar
  180. Weiss JM, Goodman PA, Losito BG, Corrigan S, Charry JM, Bailey WH: Behavioral depression produced by an uncontrollable stressor: Relationship to norepinephrine, dopamine and serotonin levels in various regions of rat brain. Brain Res Rev 1981; 3: 167–205. Google Scholar
  181. Wilkins JN, Carlson HE, van Vunakis H, et al: Nicotine from cigarette smoking increases circulating levels of cortisol, growth hormone, and prolactin in male chronic smokers. Psychopharmacology 1982; 70: 305–308. Google Scholar
  182. Yoshimura H, Fujiwara M, Ueki S: Biochemical correlates in mouse-killing behavior of the rat: Brain acetylcholine and acetylcholinesterase after administration of delta 9-tetrahydrocannabinol. Brain Res 1974; 81: 567–570.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1993

Authors and Affiliations

  • Sanjay Dubé
    • 1
  1. 1.Mood Disorders ModuleWestern Psychiatric Institute and ClinicPittsburghUSA

Personalised recommendations